KZA Stock Overview
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Kazia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.15 |
| 52 Week High | AU$0.24 |
| 52 Week Low | AU$0.07 |
| Beta | 2 |
| 1 Month Change | -3.13% |
| 3 Month Change | -8.82% |
| 1 Year Change | -13.89% |
| 3 Year Change | -80.86% |
| 5 Year Change | -65.56% |
| Change since IPO | -95.44% |
Recent News & Updates
Recent updates
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Jun 24
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Feb 24We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned
Nov 03We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth
Sep 23We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
May 04When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?
Mar 27Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
Feb 28What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?
Feb 01
We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
Jan 06Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts
Dec 11Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?
Nov 26Shareholder Returns
| KZA | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 10.7% | -2.4% | -0.6% |
| 1Y | -13.9% | -12.3% | 7.7% |
Return vs Industry: KZA underperformed the Australian Biotechs industry which returned -12.3% over the past year.
Return vs Market: KZA underperformed the Australian Market which returned 7.7% over the past year.
Price Volatility
| KZA volatility | |
|---|---|
| KZA Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in AU Market | 15.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: KZA is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: KZA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | John Friend | https://www.kaziatherapeutics.com |
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor.
Kazia Therapeutics Limited Fundamentals Summary
| KZA fundamental statistics | |
|---|---|
| Market Cap | AU$39.00m |
| Earnings (TTM) | -AU$20.47m |
| Revenue (TTM) | AU$555.00 |
Over9,999x
P/S Ratio-1.8x
P/E RatioIs KZA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KZA income statement (TTM) | |
|---|---|
| Revenue | AU$555.00 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$555.00 |
| Other Expenses | AU$20.47m |
| Earnings | -AU$20.47m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.087 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,687,419.82% |
| Debt/Equity Ratio | 14.9% |
How did KZA perform over the long term?
See historical performance and comparison